Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday

The biopharmaceutical space as a whole proved to be one of the day's strongest areas of the entire market. Part of the reason is that investors seemed to realize their prior mistake of panic-selling shares of companies that probably won't be heavily impacted by the COVID-19 illness. The reality of the situation is that patients aren't going to forgo life-saving medicines during a global pandemic, and clinical trials for important new medicines won't come to a standstill, either.